JKJui-Hung Kao

Jui-Hung Kao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jui-Hung Kao has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrating basal and reserve salivary function defines clinically anchored functional phenotypes and contextualises salivary end points in Sjögren’s disease

    by Chiao-Feng Cheng, Ting-Yuan Lan, Jui-Hung Kao, Tseng-Cheng Chen, Min-Shu Hsieh, Yu-Heng Lin, Yi-Min Huang, Yi-Chieh Chen, Mei-Fang Cheng, Hsiao-Sang Chu, et al.

    Background: Salivary gland dysfunction in Sjögren’s disease (SjD) is clinically heterogeneous. Unstimulated whole salivary flow (UWSF) reflects basal secretion, while stimulated tests such as the Saxon test assess secretory reserve. Whether integrating these complementary domains defines clinically meaningful glandular functional states remains unclear. Methods: We conducted a retrospective cohort study of 193 anti-Sjögren’s syndrome antigen A (anti-SSA)-positive patients with SjD. Using established clinical thresholds for UWSF and the Saxon test, we defined three functional phenotypes: preserved basal and reserve (PP), partial impairment (PL/LP) and combined low function (LL). Clinical features, patient-reported outcomes, submandibular gland (SMG) gland ratio and longitudinal salivary changes were evaluated. Results: Dryness and swallowing difficulty differed significantly across phenotypes. Compared with PP, the LL phenotype exhibited higher European Alliance of Associations for Rheumatology (EULAR) Sjögren’s Syndrome Patient-Reported Index dryness (β=1.67, 95% CI 0.64 to 2.70) and increased odds of swallowing difficulty (OR 6.19, 95% CI 2.71 to 14.9) after multivariable adjustment. Histological analyses showed markedly reduced SMG preservation in LL. Longitudinally, PP showed measurable declines in UWSF and Saxon test, whereas PL/LP remained relatively stable. LL had minimal longitudinal change in UWSF and a directionally positive Saxon slope, best interpreted in the context of floor-constrained end point behaviour rather than biological recovery. Baseline-to-last transition analyses showed substantial same-phenotype retention, and most longitudinally evaluable LL patients remained below the impaired Saxon threshold throughout follow-up. Conclusion: Integrated basal-reserve functional phenotyping defines clinically and structurally anchored salivary gland functional states in SjD. This framework may support clinical stratification and state-dependent interpretation of longitudinal salivary end points in studies targeting glandular outcomes.

  • Risk of osteoporotic fractures in patients with newly diagnosed pemphigus

    by Yu‐Sheng Chang, Yi‐Chun Lin, Yu‐Ning Chien, Chin‐Fang Su, Sheng‐Hong Lin, Chien‐Chih Lai, I‐Ping Lee, Ping‐You Shen, Jui‐Hung Kao, Chi‐Ching Chang

  • Epithelial senescence predicts salivary dysfunction in Sjögren disease and glandular integrity defines residual capacity

    by Chiao-Feng Cheng, Min-Shu Hsieh, Yu-Heng Lin, Ting-Yuan Lan, Yi-Chieh Chen, Jui-Hung Kao, Yi-Min Huang, Mei-Fang Cheng, Hsiao-Sang Chu, Cheng-Hsun Lu, et al.

    Objective: To investigate whether structural integrity and epithelial senescence in the submandibular gland (SMG) predict longitudinal salivary gland dysfunction in Sjögren disease (SjD). Methods: This retrospective cohort study analysed 51 anti-SSA-positive SjD patients who underwent US-guided SMG core needle biopsy and longitudinal assessments of unstimulated whole saliva flow (UWSF). Glandular preservation was quantified as the SMG gland ratio (glandular area/total area), and epithelial senescence was assessed by p16INK4a expression in striated ductal epithelial cells. Associations with baseline and longitudinal UWSF were analysed using generalized estimating equations (GEEs). Results: The SMG gland ratio correlated positively with baseline UWSF, serologic immunologic markers and imaging scores, supporting its role as a structural integrity index. However, patients with intermediate gland ratios experienced the steepest UWSF decline over time. Ductal p16 expression exhibited an inverted U-shaped distribution across the gland ratio spectrum, peaking at moderate preservation (ratio ≈ 0.55). In longitudinal models, higher p16 expression independently predicted greater UWSF decline (P < 0.001), whereas gland ratio alone was not significant. Patients with intermediate gland ratio and high p16 burden had the most rapid decline in salivary function. Conclusion: The SMG gland ratio reflects preserved glandular structure, while p16-mediated senescence captures functional vulnerability. Senescence peaks at an intermediate preservation stage, delineating a transitional disease phase in which function deteriorates despite intact architecture. These findings support a dual-pathology framework and may inform early risk stratification and therapeutic targeting in SjD.


  • Systemic Lupus Erythematosus Severity Transitions and Related Impact on Health‐Care Utilization and Costs

    by Yu‐Sheng Chang, Jui‐Hung Kao, Wen‐Nan Huang

    Aim: This study investigated the distribution of disease severity in patients with systemic lupus erythematosus (SLE), explored its impact on health‐care resource utilization and costs, and evaluated SLE severity transitions over time. Methods: SLE patients between 2015 and 2017 in Taiwan's National Health Insurance Research Database were retrospectively analyzed, and classified into the mild, moderate, or severe SLE groups. Annual health‐care resource utilization, associated costs, lupus flare events, and severity transitions were analyzed. Results: A total of 20 181 patients with SLE were included, 29.3% of whom had mild, 60.7% had moderate, and 9.9% had severe SLE. Severity was correlated with health‐care utilization and related costs, as well as the frequency and severity of flares. Patients with severe and moderate SLE incurred 2.18 and 1.42 times greater annual medical costs than those with mild SLE, respectively. Over the 2‐year follow‐up, the severe group experienced 13.23 flares, including 1.2 severe flares, significantly higher than those experienced by the moderate (9.38 flares, 0.34 severe flares) and mild (3.61 flares, 0.04 severe flares) SLE groups. Despite consistent severity distribution over 2 years, severity transitions occurred. Approximately 60% of severe patients improved within 1 year, 13% becoming mild. Conversely, fewer mild (2.8%–3.4%) and moderate (4.5%–5.4%) patients progressed to severe status annually. Conclusion: This study offers insights into the distribution and transition patterns of SLE severity, and the correlation with health‐care utilization, costs, and flare severity/frequency within a nationwide cohort. These findings highlight the importance of targeted interventions for controlling disease severity in SLE management.

  • Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap

    by Ting-Yuan Lan, Tai-Ju Lee, Ting-Wei Chang, Tai-Chung Tseng, Pei-Hsinq Lai, Chiao-Feng Cheng, Jui-Hung Kao, Kuan-Yen Lin, Shao-Yu Pai, Cheng-Han Wu, et al.

    Objective: HBV reactivation is a critical concern for patients with autoimmune disease undergoing immunosuppressive therapy. Despite data on HBV reactivation risks associated with biologics, the impact of the new targeted immunosuppressive agents—Janus kinase inhibitors (JAKis)—remains unclear. This study aimed to evaluate the risk of HBV reactivation among patients with RA treated with JAKis, compared with those receiving TNF inhibitors (TNFis) or rituximab. Method: We conducted a retrospective analysis of patients with RA treated at the National Taiwan University Hospital from 2015 to 2023. Patients with available baseline HBV status [HBsAg, hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs), HBV DNA] who received TNFis, rituximab, or JAKis (tofacitinib, baricitinib, upadacitinib) were included. The primary outcomes were hepatitis flare in HBsAg-positive patients and HBsAg seroreversion in HBsAg-negative/anti-HBc–positive patients. Results: We included 35 HBsAg-positive patients and 339 patients with resolved HBV infection (HBsAg-negative/anti-HBc–positive). Among those with resolved HBV infection, the reactivation risk was low with TNFis (0.9%, 2.8/1000 person-years), and higher with rituximab (3.2%, 15.1/1000 person-years) and JAKis overall (2.9%, 10.3/1000 person-years). Among individual JAKis, upadacitinib had the highest incidence (6.5%, 42.8/1000 person-years), followed by baricitinib (4.7%, 19.2/1000 person-years), and tofacitinib (1.0%, 2.7/1000 person-years). Among HBsAg-positive patients, 50% of JAKi users developed a hepatitis flare, emphasizing the importance of vigilant monitoring and prophylaxis. Conclusion: Our findings reveal a non-negligible risk of HBV reactivation among RA patients receiving JAKi therapy, particularly with the more JAK1-selective JAKis. Larger registry or prospective studies are needed to validate these findings.


  • Open Access

    Epidemiology and risk of psychiatric disorders in patients with polymyositis and dermatomyositis: a nationwide population-based cohort study in Taiwan

    by I-Ping Lee, Yao-Tung Lee, Fang-Yi Wu, Chin-Fang Su, Jui-Hung Kao, Sheng-Hong Lin, Yu-Sheng Chang

    Objectives To evaluate the incidence and risk factors for psychiatric disorders, including depression and anxiety, and assess the risk of suicide in patients with polymyositis (PM) and dermatomyositis (DM). Design Retrospective cohort study. Setting Data were obtained from Taiwan’s National Health Insurance Research Database (NHIRD) between 2000 and 2018. Participants A total of 3477 patients with PM/DM and 13 908 age- and sex-matched non-PM/DM controls were included in the study. Primary and secondary outcome measures The primary outcome was the incidence and risk of psychiatric disorders in patients with PM/DM compared with controls. Secondary outcomes included the identification of risk factors for psychiatric disorders, mortality and suicide risk in the PM/DM cohort. Results The incidence rate ratio (IRR) of psychiatric disorders was significantly higher in the PM/DM cohort than in controls (IRR 1.62, 95% CI 1.39 to 1.89), with depression being the most prevalent disorder (IRR 2.25, 95% CI 1.83 to 2.75). Key risk factors included female sex, intravenous steroid therapy, and high-dose oral steroid use. Additionally, the PM/DM cohort exhibited a higher mortality rate (IRR 3.4, 95% CI 3.15 to 3.67) and elevated suicide risk (IRR 1.99, 95% CI 0.96 to 3.86) compared with controls. Conclusion Patients with PM/DM face a significantly higher risk of psychiatric disorders, mortality and suicide. Integrating mental healthcare into the routine management of PM/DM is crucial to improving patient outcomes and reducing mortality. Future research should focus on the impact of early psychiatric interventions on survival outcomes in this population.


  • OA1‐AM23‐MN‐19 | Acute Treadmill Training of FVB Mice Leads to Improved RBC Deformability and Decreased Lipid Peroxidation After Cold Storage

    by V. Laurencin, D. Lamb, D. Gordy, E. Stone, K. Hudson, S. Spitalnik, E. Hod, P. Buehler, J. Kao, T. Thomas

  • The significance of dense fine speckled pattern in antinuclear antibody‐associated rheumatic disease and coexisting autoantibodies: A propensity score‐matched cohort study

    by Chiao‐Feng Cheng, Ting‐Yuan Lan, Jui‐Hung Kao, Cheng‐Hsun Lu, Yu‐Cheng Chang, Yi‐Min Huang, Feng‐Jung Yang, Jen‐Hao Chen, Yen‐Chun Lin, Chieh‐An Chuang, et al.

    To investigate the relationship between the prevalence of antinuclear antibody (ANA) -associated rheumatic diseases (AARD) and the presence of dense fine speckled (DFS) and homogeneous patterns in ANA tests. This retrospective study enrolled adult patients with either a DFS or homogeneous pattern in their ANA test. A mixed pattern was defined as the presence of more than one pattern reported in the test. The presence of anti-DFS70 antibodies and other common autoantibodies were detected using EUROLINE ANA Profile 23. A 1:2 propensity score matching was applied to control for demographic and other interfering factors. A total of 59 patients with a DFS pattern were enrolled and compared with a matched homogeneous group. The DFS group had a significantly lower prevalence of AARD (3.4% vs. 16.9%, p = .008) and the subgroup with anti-DFS70 antibodies showed an even lower prevalence (2% vs. 20%, p = .002). Among the 33 patients with monospecific anti-DFS70 antibodies, five had a mixed pattern, and all patients with common autoantibodies had an isolated DFS pattern. The findings of this study suggest that patients with a DFS pattern in their ANA test may have a lower prevalence of AARD compared with those with a homogeneous pattern. However, an isolated DFS pattern in ANA testing does not necessarily indicate the presence of monospecific anti-DFS70 antibodies or AARD. Confirmatory testing for the monospecific anti-DFS70 antibody is mandatory to exclude AARD.